Veracyte | VCYT - Selling And Administration Expenses


Veracyte reported $50.84M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Agilent USD 465M 11M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Bruker USD 242.1M 5.1M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Illumina USD 272M 11M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Laboratory Of America USD 551M 12.4M Mar/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Siemens EUR 3.56B 45M Mar/2026
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Waters USD 394M 153.99M Mar/2026